KPT-IST-391
A Phase I Trial of Selinexor, Ruxolitinib and Methylprednisolone for Patients With Relapsed/Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 30 patients (estimated)
- Sponsors
- Oncotherapeutics
- Tags
- Exportin-1 (XPO1) Inhibitor, Selective Inhibiton of Nuclear Export (SINE)
- Trial Type
- Treatment
- Last Update
- 4 months ago
- SparkCures ID
- 2041
- NCT Identifier
- NCT06225310
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.